Dear Ms. Mitrone:

Please refer to your supplemental new drug applications dated April 26, 2002 and May 6, 2002, respectively, received May 1, 2002 and May 7, 2002, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Protonix® (pantoprazole sodium) Delayed-Release Tablets and Protonix® IV (pantoprazole sodium) for Injection.

We acknowledge receipt of your submissions dated October 21, 2002.

This supplemental new drug application provides for revisions to the PRECAUTIONS section of the package insert to add a Laboratory Tests subsection.

We completed our review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, this application is approved, effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted labeling (package inserts submitted April 26, 2002 and May 6, 2002, respectively).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplements NDA 20-987/SLR-013 and NDA 20-988/SLR-012." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Gastrointestinal and Coagulation Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Melissa Furness, Regulatory Project Manager, at (301)-827-7450.

Sincerely,

Robert L. Justice, M.D., M.S.
Division Director
Division of Gastrointestinal & Coagulation Drug Products
Office of Drug Evaluation ODE III
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Joyce Korvick
10/28/02 10:28:20 AM
for Dr, Robert Justice